Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4 of 2025– –Th ...